Health related quality of life in patients with actinic keratosis - an observational study of patients treated in dermatology specialist care in Denmark

Health and Quality of Life Outcomes

Volumn 13, Issue 1, 2015, Pages

  Tennvall, Gunnel Ragnarson ^a   Norlin, J M ^a   Malmberg, I ^b   Erlendsson, A M ^c   Haedersdal M ^c  

^a SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

^b LEO Pharma AB   (Sweden)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Actinic keratosis; AKQoL; DLQI; EQ 5D; Health related quality of life

Indexed keywords

ACTINIC KERATOSIS; ACTINIC KERATOSIS QUALTY OF LIFE QUESTIONNAIRE; ARTICLE; ASSESSMENT OF HUMANS; CONTROLLED STUDY; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; EUROQOL FIVE DIMENSIONAL QUESTIONNAIRE; EUROQOL VISUAL ANALOGUE SCALE; HUMAN; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT CARE; PHYSICIAN ATTITUDE; PROFESSIONAL COMPETENCE; PROFESSIONAL KNOWLEDGE; QUALITY OF LIFE; SYNDROME DELINEATION; ADULT; AGED; CROSS-SECTIONAL STUDY; DENMARK; FEMALE; HEALTH STATUS INDICATOR; KERATOSIS, ACTINIC; MALE; MIDDLE AGED; NONPARAMETRIC TEST; PSYCHOLOGY; QUESTIONNAIRE; SELF CONCEPT; STANDARDS;

DERMATOLOGICAL AGENT;

ADULT; AGED; CROSS-SECTIONAL STUDIES; DENMARK; DERMATOLOGIC AGENTS; FEMALE; HEALTH STATUS INDICATORS; HUMANS; KERATOSIS, ACTINIC; MALE; MIDDLE AGED; QUALITY OF LIFE; SELF CONCEPT; STATISTICS, NONPARAMETRIC; SURVEYS AND QUESTIONNAIRES;

EID: 84937850209     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/s12955-015-0295-4     Document Type: Article

References (47)

1. Dodson JM, DeSpain J, Hewett JE, Clark DP. Malignant potential of actinic keratoses and the controversy over treatment. A patient-oriented perspective. Arch Dermatol. 1991;127:1029-31.
2. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet. 1988;1:795-7.
3. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol. 2000;42:23-4.
4. Marks R, Foley P, Goodman G, Hage BH, Selwood TS. Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol. 1986;115:649-55.
5. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42:4-7.
6. Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol. 1994;131:455-64.
7. Harvey I, Frankel S, Marks R, Shalom D, Nolan-Farrell M. Non-melanoma skin cancer and solar keratoses. I. Methods and descriptive results of the South Wales Skin Cancer Study. Br J Cancer. 1996;74:1302-7.
8. Memon AA, Tomenson JA, Bothwell J, Friedmann PS. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol. 2000;142:1154-9.
9. Naldi L, Chatenoud L, Piccitto R, Colombo P, Placchesi EB, La Vecchia C. Prevalence of actinic keratoses and associated factors in a representative sample of the Italian adult population: Results from the Prevalence of Actinic Keratoses Italian Study, 2003-2004. Arch Dermatol. 2006;142:722-6.
10. Barr BB, Benton EC, McLaren K, Bunney MH, Smith IW, Blessing K, et al. Human papilloma virus infection and skin cancer in renal allograft recipients. Lancet. 1989;1:124-9.
11. Otuki MF, Reis RC, Cabrini D, Prudente AS, Horinouchi CD, Correr CJ. Patient-reported outcomes in psoriasis research and practice. Br J Dermatol. 2011;165:1361-2.
12. NICE: Guideline Development Methods. 8 Incorporating health economics in guidelines and assessing resource impact. 2014. http://www.nice.org.uk/niceMedia/pdf/GDM_Chapter8_0305.pdf Assessed 11 March 2014.
13. TLV. General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2). http://www.tlv.se/Upload/English/Guidelines-for-economic-evaluations-LFNAR-2003-2.pdf2003 .
14. Esmann S, Vinding GR, Christensen KB, Jemec GB. Assessing the influence of actinic keratosis on patients' quality of life: the AKQoL questionnaire. Br J Dermatol. 2013;168:277-83.
15. Gibbons E, Casanas i Comabella C, Fitzpatrick R. A structured review of patient-reported outcome measures for patients with skin cancer, 2013. Br J Dermatol. 2013;168:1176-86.
16. Lee K, Weinstock M. Prospective quality of life impact of actinic keratoses: observations from the veterans affairs topical tretinoin chemoprevention trial. Acta Derm Venereol. 2011;91:101-2.
17. Weinstock MA, Lee KC, Chren MM, Marcolivio K. Quality of life in the actinic neoplasia syndrome: The VA Topical Tretinoin Chemoprevention (VATTC) Trial. J Am Acad Dermatol. 2009;61:207-15.
18. Drummond MF, Sculpher M, Torrance G, O'Brian B, Stoddart G. Methods for the economic evaluation of health care programmes. New York: Oxford University Press; 2005.
19. Brooks R. EuroQol: the current state of play. Health policy. 1996;37:53-72.
20. Norlin JM, Steen Carlsson K, Persson U, Schmitt-Egenolf M. Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients. Br J Dermatol. 2012;166:797-802.
21. Ragnarson Tennvall G, Hjortsberg C, Bjarnason A, Gniadecki R, Heikkila H, Jemec GB, et al. Treatment patterns, treatment satisfaction, severity of disease problems, and quality of life in patients with psoriasis in three Nordic countries. Acta Derm Venereol. 2013;93:442-5.
22. Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159:997-1035.
23. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210-6.
24. Gholam P, Kroehl V, Enk AH. Dermatology life quality index and side effects after topical photodynamic therapy of actinic keratosis. Dermatology. 2013;226:253-9.
25. Olsen EA, Abernethy ML, Kulp-Shorten C, Callen JP, Glazer SD, Huntley A, et al. A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol. 1991;24:738-43.
26. Erlendsson AM, Egekvist H, Lorentzen HF, Philipsen PA, Stausböl-Grön B, Stender IM, et al. Actinic Keratosis: Disease characteristics and treatment patterns in Danish dermatology clinics - a cross-sectional study. Int J Dermatol. in press
27. EuroQol group. EuroQol-a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy. 1990;16:199-208.
28. van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5 L: mapping the EQ-5D-5 L to EQ-5D-3 L value sets. Value Health. 2012;15:708-15.
29. Both H, Essink-Bot ML, Busschbach J, Nijsten T. Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol. 2007;127:2726-39.
30. Bronsard V, Paul C, Prey S, Puzenat E, Gourraud PA, Aractingi S, et al. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24 Suppl 2:17-22.
31. Rhee JS, Matthews BA, Neuburg M, Smith TL, Burzynski M, Nattinger AB. Skin cancer and quality of life: assessment with the Dermatology Life Quality Index. Dermatol Surg. 2004;30:525-9.
32. Steinbauer J, Koller M, Kohl E, Karrer S, Landthaler M, Szeimies RM. Quality of life in health care of non-melanoma skin cancer - results of a pilot study. J Dtsch Dermatol Ges. 2011;9:129-35.
33. Badia X, Mascaro JM, Lozano R. Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQI. The Cavide Research Group. Br J Dermatol. 1999;141:698-702.
34. Hjortsberg C, Bergman A, Bjarnason A, Heikkila H, Hjelmgren J, Svensson A, et al. Are treatment satisfaction, quality of life, and self-assessed disease severity relevant parameters for patient registries? Experiences from Finnish and Swedish patients with psoriasis. Acta Derm Venereol. 2011;91:409-14.
35. Klassen AF, Newton JN, Mallon E. Measuring quality of life in people referred for specialist care of acne: comparing generic and disease-specific measures. J Am Acad Dermatol. 2000;43:229-33.
36. Hadley J, Tristani-Firouzi P, Hull C, Florell S, Cotter M, Hadley M. Results of an investigator-initiated single-blind split-face comparison of photodynamic therapy and 5 % imiquimod cream for the treatment of actinic keratoses. Dermatol Surg. 2012;38:722-7.
37. Ghatnekar O, Ljungberg A, Wirestrand LE, Svensson A. Costs and quality of life for psoriatic patients at different degrees of severity in southern Sweden - a cross-sectional study. Eur J Dermatol. 2012;22:238-45.
38. Moberg C, Alderling M, Meding B. Hand eczema and quality of life: a population-based study. Br J Dermatol. 2009;161:397-403.
39. Poole CD, Chambers C, Sidhu MK, Currie CJ. Health-related utility among adults with atopic dermatitis treated with 0.1 % tacrolimus ointment as maintenance therapy over the long term: findings from the Protopic CONTROL study. Br J Dermatol. 2009;161:1335-40.
40. Scott FT, Johnson RW, Leedham-Green M, Davies E, Edmunds WJ, Breuer J. The burden of Herpes Zoster: a prospective population based study. Vaccine. 2006;24:1308-14.
41. Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes. 2006;4:71.
42. Weiss SC, Rehmus W, Kimball AB. An assessment of the cost-utility of therapy for psoriasis. Ther Clin Risk Manag. 2006;2:325-8.
43. Sorensen J, Davidsen M, Gudex C, Pedersen KM, Bronnum-Hansen H. Danish EQ-5D population norms. Scand J Public Health. 2009;37:467-74.
44. Pereira FR, Basra MK, Finlay AY, Salek MS. The role of the EQ-5D in the economic evaluation of dermatological conditions and therapies. Dermatology. 2012;225:45-53.
45. Burstrom K, Johannesson M, Diderichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res. 2001;10:621-35.
46. Swinscow TDV, Campbell MJ. Statistics at square one. 10th ed. London: BMJ Books; 2002.
47. Nijsten T. Dermatology life quality index: time to move forward. J Invest Dermatol. 2012;132:11-3.